BioSpace News Archive

Daiichi Sankyo and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

Tetra Bio-Pharma Inc. announced that it has entered into a subscription agreement with Global Corporate Finance Opportunities 16, an investment vehicle advised by Alpha Blue Ocean Inc., whereby Tetra has agreed to issue to the Investor senior unsecured convertible debentures in the aggregate principal amount of up to $6,000,000, and warrants to purchase common shares in the capital of the Company.

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that it has terminated the underwritten public offering of its Class A common stock previously announced on August 10, 2022.